Fortress Biotech, Inc. demonstrated robust progress in the second quarter of 2026, primarily driven by the commercial scaling of Emrosi, its leading dermatology product, and strategic advancements in its diverse pipeline. The company significantly enhanced its financial position following the monetization of a Priority Review Voucher, bolstering its cash reserves to $196.6 million.
Journey Medical, a subsidiary, played a crucial role in the quarter's success, reporting sequential prescription growth and improved market access for Emrosi. Emrosi's net product revenue reached $17.8 million, contributing to the consolidated net revenue increase of 14% to $18.7 million. The product's total prescriptions rose by 20% sequentially, with a notable increase in unique prescribers, indicating strong market acceptance and physician confidence. Furthermore, the company expanded its dermatology portfolio with the introduction of Eurax Cream in July 2026 and advanced other partner programs, including Crystalys Therapeutics, which secured significant funding for late-stage development. These initiatives underscore Fortress Biotech's commitment to innovation and market expansion within the dermatology and rare disease sectors.
Despite a reported net loss attributable to common stockholders of $2.5 million, management remains optimistic, forecasting 2026 as a landmark year for both revenue growth and profitability. This outlook is supported by effective expense management, evidenced by reduced SG&A and R&D expenditures, and a focus on leveraging its commercial infrastructure for sustainable growth. The company's strategic approach to enhancing payer coverage for Emrosi is also expected to drive average selling price improvements, further contributing to its financial health. Through these concerted efforts in commercialization, pipeline development, and financial discipline, Fortress Biotech is charting a course toward long-term value creation and improved patient outcomes.
Fortress Biotech's strategic focus on innovation, market expansion, and financial prudence exemplifies a commitment to not only commercial success but also to enhancing healthcare. By delivering advanced treatment options and ensuring broader patient access, the company embodies the positive impact that dedicated scientific and business endeavors can have on global health and well-being, fostering a future of improved care and opportunity.
